Piper Sandler analyst Biren Amin raised the firm’s price target on Sarepta (SRPT) to $16 from $15 and keeps a Neutral rating on the shares. The firm says its latest physician survey of 10 U.S.-based neurologists who treat Duchenne Muscular Dystrophy highlights a notable contraction in Elevidys use through Q3 2025, driven primarily by safety-related headwinds, but also points to modest recovery and potential stabilization heading into year-end and 2026. Overall, Piper views these results as supportive of a near-term reset followed the potential for a gradual recovery, and have conservatively adjusted its Q3 and Q4 Elevidys sales forecasts to align with these findings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta’s Gene Therapy Study: A Potential Game-Changer for Duchenne Muscular Dystrophy
- Sarepta’s Gene Therapy Study for Young DMD Patients: A Market Game-Changer?
- Sarepta’s Observational Study on DMD Therapies: Market Insights
- Sarepta and Hansa’s Gene Therapy Study: A Potential Breakthrough for DMD Treatment
- Sarepta Therapeutics’ Long-term Study on SRP-9001: A Boost for Investor Confidence?